Therapeutic value of growth hormone;Valor terapéutico de la hormona del crecimiento

Medicina Clinica

Volumn 130, Issue 7, 2008, Pages 261-262

  Webb, Susan M ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN;

AGING; BONE DENSITY; BONE MASS; DRUG APPROVAL; EDITORIAL; GROWTH HORMONE DEFICIENCY; HORMONE RELEASE; HUMAN; MORTALITY; PRADER WILLI SYNDROME; QUALITY OF LIFE; SHORT FORM 36; SPAIN; TREATMENT INDICATION; TURNER SYNDROME;

EID: 42049097475     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13116551     Document Type: Editorial

References (10)

1. Ministerio de Sanidad y Consumo. Comunicación sobre riesgos de medicamentos para profesionales sanitarios. Riesgos del uso de hormona de crecimiento en personas sanas y paso a uso hospitalario. Ref.: 2005/08. Madrid: Ministerio de Sanidad y Consumo; 22 de abril de 2005.
2. Consensus Statement. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998;83:379-81.
3. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-8.
4. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. Lancet. 2001;357:425-31.
5. Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett M, Bates PC, Valk NK J, et al; and the Adult Growth Hormone Deficiency study HypoCCS group. Adult growth hormone defíciency syndrome patients demonstrate heterogeneity between childhood onset and adult onset. J Clin Endocrinol Metab. 1997;82:82-8.
6. Svensson J, Johannsson G, Bengtsson BA. Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol (Oxf). 1997;46:579-86.
7. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf). 1994;41:351-7.
8. Clasey JL, Weltman A, Patrie J, Weltman JY, Pezzoli S, Bouchard C, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab. 2001;86:3845-52.
9. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SWJ, et al; on behalf of the HypoCCS Advisory Board. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by QLS-H©. J Clin Endocrinol Metab. 2004;89:1684-93.
10. Hernberg-Ståhl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P, et al; on behalf of the KIMS Study Group. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab. 2001;86:5277-81.